Impact of regulatory issues on drug development for the CNS

被引：0
|
作者：
Kuruma, I
机构：
来源：
PRECLINICAL AND CLINICAL STRATEGIES FOR THE TREATMENT OF NEURODEGENERATIVE, CEREBROVASCULAR AND MENTAL DISORDERS | 1996年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：281 / 282
页数：2
相关论文
共 50 条
  • [1] Safety and regulatory requirements and challenge for CNS drug development
    Gad, Shayne C.
    NEUROBIOLOGY OF DISEASE, 2014, 61 : 39 - 46
  • [2] What regulatory science can bring for CNS drug development
    Gispen-de Wied, Christine
    Stoyanova-Beninska, Violeta
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 (07) : 967 - 968
  • [3] Enantiomeric drug development: Issues, considerations, and regulatory requirements
    Srinivas, NR
    Barbhaiya, RH
    Midha, KK
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 90 (09) : 1205 - 1215
  • [4] Human cytomegalovirus and transplantation: drug development and regulatory issues
    McIntosh, Megan
    Hauschild, Benjamin
    Miller, Veronica
    JOURNAL OF VIRUS ERADICATION, 2016, 2 (03) : 143 - 148
  • [5] The use of imaging as biomarkers in drug development: Regulatory issues worldwide
    Katz, R
    Wagner, HN
    Fauntleroy, M
    Kuwert, T
    Frank, R
    JOURNAL OF CLINICAL PHARMACOLOGY, 2001, : 118S - 118S
  • [6] Regulatory and drug development issues related to female sexual dysfunction
    Allen, SS
    JOURNAL OF SEX & MARITAL THERAPY, 2002, 28 : 11 - 16
  • [7] FOOD AND DRUG REGULATORY ISSUES
    STRIBLING, J
    PICUT, C
    VETERINARY CLINICS OF NORTH AMERICA-SMALL ANIMAL PRACTICE, 1993, 23 (05) : 991 - 1005
  • [8] A tiered approach to address regulatory drug metabolite-related issues in drug development
    Ma, Shuguang
    Chowdhury, Swapan K.
    BIOANALYSIS, 2014, 6 (05) : 587 - 590
  • [9] Orphan drug development: The impact of regulatory and reimbursement frameworks
    Huang, Yu-Jun
    Chao, Wan-Yu
    Wang, Chi-Chuan
    Chang, Lin-Chau
    DRUG DISCOVERY TODAY, 2022, 27 (06) : 1724 - 1732
  • [10] Regulatory and legal issues in development of controlled drug delivery products.
    Chan, K
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 221 : U432 - U432
12345